US 11,896,646 B2
Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
David Stover, Los Angeles, CA (US); Dhruba Bharali, Sherman Oaks, CA (US); Bruce A Hay, Niskayuna, NY (US); and Tahmineh Safaie, Los Angeles, CA (US)
Assigned to Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed by Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed on Oct. 14, 2022, as Appl. No. 17/803,703.
Application 17/803,703 is a continuation of application No. 17/300,227, filed on Apr. 16, 2021, granted, now 11,679,141.
Application 17/300,227 is a continuation of application No. 16/974,306, filed on Dec. 21, 2020, granted, now 11,744,874.
Prior Publication US 2023/0270819 A1, Aug. 31, 2023
Int. Cl. A61K 31/4188 (2006.01); A61K 47/69 (2017.01); A61K 38/17 (2006.01); A61K 47/54 (2017.01); A61K 45/06 (2006.01)
CPC A61K 38/177 (2013.01) [A61K 45/06 (2013.01); A61K 47/543 (2017.08); A61K 47/6911 (2017.08)] 16 Claims
 
1. A Toll-like receptor (TLR) prodrug composition comprising,
(i) a drug moiety;
(ii) a lipid moiety; and
(iii) a linkage unit (“LU”),
whereby the drug moiety comprises a TLR agonist and whereby the LU conjugates the drug moiety with the lipid moiety and wherein the TLR prodrug has the following chemical structure:

OG Complex Work Unit Chemistry